1. Мельниченко Г.А., Стилиди И.С., Алексеев Б.Я., Горбунова В.А., Бельцевич Д.Г., Райхман А.О., Кузнецов Н.С., Жуков Н.В., Бохян В.Ю. Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака. Проблемы эндокринологии. 2014; 60(2): 51-67. doi: 10.14341/probl201460251-67
2. Lloyd RV, Osamura RY, Klöppel G, Rosai J, eds. WHO Classification of Tumours of Endocrine Organs. Fourth Edition. Lyon: IARC; 2022
3. Селиванова Л.С., Рослякова А.А., Боголюбова А.В., Тертычный А.С., Бельцевич Д.Г., Абросимов А.Ю., Мельниченко Г.А. Молекулярно-генетические маркеры и критерии прогноза адренокортикального рака. Архив патологии. 2019;81(5):92-96. doi: 10.17116/patol20198105192
4. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667. doi: 10.1677/erc.1.01029
5. Министерство здравоохранения Российской Федерации. Перечень редких (орфанных) заболеваний. https://www.rosminzdrav.ru/documents/8048 [ссылка активна на 27.10.2019]
6. Bisceglia M. et al. Adrenocortical oncocytic tumors: Report of 10 cases and review of the literature // Int. J. Surg. Pathol. 2004. Vol. 12, № 3. P. 231–243.
7. Adrenal Cortical Carcinoma. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017
8. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. EJE. 2018; 179(4): G1-G46. doi: 10.1530/EJE-18-0608.
9. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res ClinEndocrinolMetab. 2009;23(2):273-89. doi: 10.1016/j.beem.2008.10.008
10. Chuang B, Fassnacht M. Adrenocortical carcinoma: clinical update. J ClinEndocrinolMetab. 2006;91(6):2027-37. doi: 10.1210/jc.2005-2639
11. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg. 1997; 132(2):914–919. doi:10.1001/archsurg.1997.01430320116020
12. Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513-27. doi: 10.1530/EJE-09-0234.
13. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: 10.1530/EJE-16-0467.
14. Селиванова Л.С., Рослякова А.А., Коваленко Ю.А., Боголюбова А.В., Тертычный А.С., Бельцевич Д.Г., Абросимов А.Ю., Мельниченко Г.А. Современные критерии диагностики адренокортикального рака. Архив патологии. 2019;81(3):66-73. https://doi.org/10.17116/patol20198103166
15. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников. Эндокринная хирургия. 2009;3(1):19–23.
16. Young WFJr. The Incidentally Discovered Adrenal Mass. N Engl J Med. 2007;356:601-10. doi: 10.1056/NEJMcp065470
17. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298-302. doi: 10.1007/BF03344099
18. Nieman LK, Biller BMK, Findling JW et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40. doi: 10.1210/jc.2008-0125.
19. Terzolo M, Reimondo G, Bovio S, Angeli A Subclinical Cushing’s syndrome. Pituitary. 2004;7(4):217-223. doi: 10.1007/s11102-005-4024-6
20. Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, Trésallet C, Amar L, Rault A, Henry JF, Carnaille B. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012;36(6):1382-8. doi: 10.1007/s00268-012-1488-1.
21. Li XG, Zhang DX, Li X, Cui XG, Xu DF, Li Y, Gao Y, Yin L, Ren JZ Adrenocorticotropic hormone-producing pheochromocytoma: a case report and review of the literature. Chin Med J (Engl). 2012;125(6):1193-1196. doi: 10.3760/cma.j.issn.0366-6999.2012.06.042
22. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E, Caron P. Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecol Endocrinol. 2009;25(9):624-627. doi: 10.1080/09513590903015411
23. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006;29(5):471-82. doi: 10.1007/BF03344133
24. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19(5):647-672. doi: 10.1210/edrv.19.5.0346
25. Pecori Giraldi F, Ambrogio AG, De Martin M, et al. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92(11):4123-9. doi: 10.1210/jc.2007-0596
26. Mitchell IC, Auchus RJ, Juneja K, et al. “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007;142(6):900-905. doi: 10.1016/j.surg.2007.10.001
27. Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. doi: 10.1016/S0889-8529(05)70115-8
28. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur J Endocrinol. 2002;146(1):61-66. doi: 0.1530/eje.0.1460061
29. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92:4069-4079. doi: 10.1210/jc.2007-1720
30. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol. 2003;29(6):483-490
31. Kinney M, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002; 16:359-369. doi: 10.1053/jcan.2002.124150
32. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metab. 2008;93(9):3266-3281.
33. Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г. и др. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма. Consilium Medicum. 2017; 19(4): 75–85.
34. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. Москва: Практ. медицина; 2005;47-70.
35. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and 2279 treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin 2280 Endocrinol Metab 2013 98 4565-4592.
36. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004; 60:273-287. 19:540-544.
37. Metser U, Miller E, Lerman H et al. 18F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl Med. 2006;47(1):32-37.
38. M. Blake, P. Prakash, C. Cronin. PET/CT for Adrenal Assessment Am J Roentgenology. 2010;195(2):195.
39. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F] fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006; 91:2665.
40. Leboulleux S, Dromain C, Bonniaud G et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006; 91:920.
41. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997; 47:279-283.
42. Sasano, H. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma / H. Sasano, T. Suzuki, T. Moriya // Endocr. Pathol. – 2006. – Vol. 17, №4. – P. 345-354.
43. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011; 2:354.
44. Giordano T.J. et al. Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting // Hum. Pathol. Elsevier Inc., 2021. Vol. 110. P. 50–61.
45. Макроскопическое исследование биопсийного и операционного материала. Руководство для врачей-патологоанатомов / под ред. Ю.А. Криволапова. – М.: Практическая медицина, 2020. – 352 с.: ил.
46. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors // American Journal of Surgical Pathology. 1984. Vol. 8, № 3. P. 163–169.
47. Pennanen M. et al. Helsinki score - A novel model for prediction of metastases in adrenocortical carcinomas // Hum. Pathol. Elsevier Inc., 2015. Vol. 46, № 3. P. 404–410.
48. Aubert S. et al. Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors // Am. J. Surg. Pathol. 2002. Vol. 26, № 12. P. 1612–1619.
49. Бохян В.Ю., Павловская А.И., Губина Г.И., Стилиди И. С. Клиническая оценка гистологических систем диагностики адренокортикальных опухолей. Архив патологии, 2015;77(3):17-22.
50. Бохян В.Ю., Стилиди И. С., Павловская А.И. Сравнительный клинический анализ гистологических систем диагностики адренокортикальных опухолей. Вопросы онкологии, 2015;61(6):925-931.
51. Ткачук А.В. и др. Адренокортикальный рак: морфологические варианты, иммуногистохимическая характеристика // Архив патологии. 2021. Т. 83, №3. Стр. 10-18.
52. Dehner L.P. et al. Adrenal Cortical Neoplasms in Children: Why So Many Carcinomas and Yet So Many Survivors? // Pediatric and Developmental Pathology. 2009. №12. P. 284–91.
53. Wieneke J.A. et al. Adrenal cortical neoplasms in the pediatric population: A clinicopathologic and immunophenotype analysis of 83 patients // Am J Surg Pathol. 2003. №27. P. 867-881.
54. Mete O. et al. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma // Am. J. Surg. Pathol. 2018. Vol. 42, № 2. P. 201–213.
55. Martins-Filho S.N. et al. Clinical Impact of Pathological Features Including the Ki-67 Labeling Index on Diagnosis and Prognosis of Adult and Pediatric Adrenocortical Tumors // Endocr. Pathol. Springer US, 2021. Vol. 32, № 2. P. 288–300.
56. Duregon E. et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma // Mod. Pathol. Nature Publishing Group, 2014. Vol. 27, № 9. P. 1246–1254.
57. Beuschlein F. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection // J. Clin. Endocrinol. Metab. 2015. Vol. 100, № 3. P. 841–849.
58. Mete O. et al. Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms // Endocr. Pathol. Endocrine Pathology, 2018. Vol. 29, № 2. P. 137–149.
59. Juhlin C.C. et al. What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics // Endocrine Pathology. Springer US, 2021. Vol. 32, № 1. P. 102–133.
60. Селиванова Л.С. и др. Молекулярно-генетические маркеры и критерии прогноза адренокортикального рака // Архив патологии. 2019. Т. 81, №5. Стр. 92-96.
61. Picard C. et al. Revisiting the role of the pathological grading in pediatric adrenal cortical tumors: results from a national cohort study with pathological review // Mod. Pathol. Springer US, 2019. Vol. 32, № 4. P. 546–559.
62. Domènech M. et al. Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome // J Clin Endocrinol Metab. 2021. Vol. 106 №2. P. 318-325.
63. Volante M. et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer // Clin. Cancer Res. 2012. Vol. 18, № 12. P. 3452–3461.
64. Ronchi C.L. et al. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma // PLoS One. 2014. Vol. 9, № 8.
65. Adrenal Cortical Carcinoma. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017.
66. Else T. Association of Adrenocortical Carcinoma with Familial Cancer Susceptibility Syndromes. Mol Cell Endocrinol. 2012; 351(1): 66–70. doi: 10.1016/j.mce.2011.12.008
67. Стилиди И.С., Бохян В.Ю., Карманов И.Е., Перегородиев И.Н., Абгарян М.Г. Поражение нижней полой вены при адренокортикальном раке: результаты хирургического лечения. Анналы хирургии. 2016; 21 (4): 248-256.
68. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001; 25:914-926
69. Reibetanz J, Jurowich C, Erdogan I et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012; 255:363
70. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012 152(1):123-32
71. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992;112(6):972-979.
72. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992;112(6):972-979.
73. Филиппова ОВ. Адренокортикальный рак: клинические проявления и морфологическая диагностика / Филиппова О.В., Хмельницкая Н.М. // Медицинский альманах. 2011; 5:113-116.
74. Wängberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010; 17:265.
75. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., Антонов А.К., Смелкова Н.И.. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. Вестник новых медицинских технологий (электронное издание). 2013;1 [Электронный ресурс].
76. Casola G, Nicolet V, van Sonnenberg E et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology. 1986; 159:733-735.
77. Leboulleux S, Deandreis D, Ghuzlan A Al et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal сarcinomatosis? Eur J Endocrinol. 2010; 162:1147-1153
78. Brix D, Allolio B, Fenske W et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010; 58:609.
79. Miller BS, Gauger PG, Hammer GD et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010; 395:955/
80. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6(8):719-726
81. Bellantone R, Ferrante A, Boscherini M, et al.: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997,122:1212-1218.
82. Porpiglia F, Fiori C, Scarpa RM et al. The role of surgery in the management of recurrent adrenocortical carcinoma: results of a retrospective study. Eur Urol Suppl. 2009;8(4):305.
83. Terzolo, M. Adjuvant mitotane treatment for adrenocortical carcinoma / M. Terzolo Angeli A, Fassnacht M et al. // N. Engl. J. Med. – 2007. – Vol. 356, №23. – P. 2372-2380.
84. Huang H, FojoT. Adjuvant mitotane for adrenocortical cancer – a recurring controversy. Journal of Clinical Endocrinology and Metabolism. 2008; 93(10): 3730–3732. doi: 10.1210/jc.2008-0579.
85. Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant Mitotane for Adrenocortical Cancer—Working through Uncertainty. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(6):1879–1880. doi:10.1210/jc.2009-0120.
86. Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism.2017;102:1358–1365. doi:10.1210/jc.2016-2894.
87. Terzolo M, Fassnacht M, Perotti P. et al. Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. J Endocr Soc. 2021 May 3;5(Suppl 1):A166–7. doi: 10.1210/jendso/bvab048.336. PMCID: PMC8265733.
88. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf). 1989; 31:51-57.
89. Basile V, Puglisi S, Altieri B. et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021 Apr 4;11(4):269. doi: 10.3390/jpm11040269. PMID: 33916613; PMCID: PMC8066814.
90. Calabrese A, Basile V, Puglisi S et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol. 2019 Jun 1;180(6):387-396. doi: 10.1530/EJE-18-0923. PMID: 30991359.
91. Decker RA, Kuehner ME. Adrenocortical carcinoma. Am Surg. 1991; 57:502-513.
92. Brix D, Allolio B, Fenske W et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010; 58:609.
93. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6:386-394.
94. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000; 33:1197-1200.
95. Krzisnik C, Petric G, Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p -DDD in a child. Pediatr Hematol Oncol. 1988; 5:65-69.
96. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. Endocrinol Invest. 2014;37(3):207-17. doi: 10.1007/s40618-013- 0049.
97. Huang H, FojoT. Adjuvant mitotane for adrenocortical cancer – a recurring controversy. Journal of Clinical Endocrinology and Metabolism. 2008; 93(10): 3730–3732. doi: 10.1210/jc.2008-0579.
98. Fassnacht M, Dekkers O, Else T. et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. EJE. 2018; 179(4): G1-G46. doi: 10.1530/EJE18-0608.
99. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994; 69:947-951.
100. Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92:1385-1392.
101. Poirier J, Gagnon N, Terzolo M et al. Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma. Cancers (Basel). 2020 Mar 10;12(3):639. doi: 10.3390/cancers12030639. PMID: 32164326; PMCID: PMC7139486.
102. Fassnacht M, Arlt W, Bancos I et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: 10.1530/EJE-16-0467.
103. Fassnacht M, Dekkers OM, Else T et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018 Oct 1;179(4): G1-G46. doi: 10.1530/EJE-18-0608. PMID: 30299884.
104. Kimpel O, Bedrose S, Megerle F et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer. 2021 Oct;125(9):1233-1238. doi: 10.1038/s41416-021-01513-8. Epub 2021 Aug 16. PMID: 34400803; PMCID: PMC8548516.
105. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study GroupN Engl J Med. 2012;366(23):2189.
106. Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism.2017;102:1358–1365. doi:10.1210/jc.2016-2894.
107. Megerle F, Herrmann W, Schloetelburg W et al. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686-1695. doi: 10.1210/jc.2017-02591. PMID: 29452402.
108. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004; 60:273-287. 19:540-544.
109. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al.: Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 45 (3): 265-73, 2005.
110. Zancanella P, Pianovski MA, Oliveira BH, et al.: Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J Pediatr Hematol Oncol 28 (8): 513-24, 2006.
111. Matthew T. Campbell, Emily Lemke, Khaled M. Elsayes et al. A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma. Journal of Clinical Oncology 2018 36:15_suppl, e16591-e16591.
112. Laganà M, Grisanti S, Cosentini D et al. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. Cancers (Basel). 2020 Apr 10;12(4):941. doi: 10.3390/cancers12040941. PMID: 32290298; PMCID: PMC7226395.
113. Raymond VM, Everett JN, Furtado LV et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013 Aug 20;31(24):3012-8. doi: 10.1200/JCO.2012.48.0988. Epub 2013 Jul 22. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612. PMID: 23752102; PMCID: PMC3739861.
114. Maio M, Ascierto PA, Manzyuk L et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022 Sep;33(9):929-938. doi: 10.1016/j.annonc.2022.05.519. Epub 2022 Jun 6. PMID: 35680043.
115. Raj N, Zheng Y, Kelly V et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020 Jan 1;38(1):71-80. doi: 10.1200/JCO.19.01586. Epub 2019 Oct 23. PMID: 31644329; PMCID: PMC7351334.
116. Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018;6(1):111.
117. Zhulikov Ya., Kovalenko E., Bokhian V. et al. Efficiency of platinum-based chemotherapy re-induction for adrenocortical cancer treatment, SCIREA Journal of Clinical Medicine. Vol. 7, No. 5, 2022, pp. 302 - 311. DOI: 10.54647/cm32932.
118. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/ third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445-453.
119. Henning JEK, Deutschbein T, Altieri B, et al. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. J Clin Endocrinol Metab. 2017;102(11):4323-4332.
120. Жуликов Я.А., Коваленко Е.И., Бохян В.Ю. et al. Эффективность химиотерапии по схеме GemCap + митотан во 2-й и последующих линиях лечения метастатического адренокортикального рака. Тазовая хирургия и онкология. 2022;12(3):36-42. https://doi.org/10.17650/2686-9594-2022-12-3-36-42
121. Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism.2017;102:1358–1365. doi:10.1210/jc.2016-2894
122. Fassnacht M, Hahner S, Polat B, et al. Effcacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism. 2006; 91:4501–4504.
123. Habra MA, Ejaz S, Feng L, et al. A Retrospective Cohort Analysis of the Effcacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism. 2013; 98:192–197. doi:10.1210/jc.2012-2367)
124. Sabolch A, Else T, Griffth KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2015; 92:252–259. doi:10.1016/j.ijrobp.2015.01.007
125. Cerquetti L, Bucci B, Marchese R, et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocrine-Related Cancer. 2008; 15:623–634. doi:10.1677/erc.1.1315
126. Krzisnik C, Petric G, Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p -DDD in a child. Pediatr Hematol Oncol. 1988; 5:65-69.
127. Huang H, FojoT. Adjuvant mitotane for adrenocortical cancer – a recurring controversy. Journal of Clinical Endocrinology and Metabolism. 2008; 93(10): 3730–3732. doi: 10.1210/jc.2008-0579
128. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study GroupN Engl J Med. 2012;366(23):2189.
129. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. Journal of Clinical Endocrinology and Metabolism 2013 98 161–171. (https://doi.org/10.1210/jc.2012-2851)]
130. Abiven-Lepage G, Coste J, Tissier F, et al. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. European Journal of Endocrinology 2010;163:793–800. doi:10.1530/EJE-10-0412)
131. Sirianni R, Zolea F, Chimento A, et al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. Journal of Clinical Endocrinology and Metabolism. 2012;97: E2238–E2250. doi:10.1210/jc.2012-2374
132. Icard P, Goudet P, Charpenay C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg. 2001; 25:891-897.
133. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6:386-394
134. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984; 20:47-53.
135. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994; 69:947-951.
136. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001; 92:1113-1121.
137. Johanssen S, Hahner S, Saeger W, et al. Defcits in the management of patients with adrenocortical carcinoma in germany. Deutsches Arzteblatt International.2010;107: U885–U889.
138. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113:3130–3136. (doi:10.1002/cncr.23886)
139. Libe R, Borget I, Ronchi CL, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology.
140. Miller BS, Gauger PG, Hammer GD, Giordano TJ & Doherty GM. Proposal for modifcation of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Archives of Surgery 2010 395 955–961. (https://doi.org/10.1007/s00423-010-0698-y)
141. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic signifcance in adrenocortical carcinoma. American Journal of Surgical Pathology. 1989; 13:202–206. doi:10.1097/00000478-198903000-00004Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of aproliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal.2008;55:49–55.doi: org/10.1507/endocrj.K07-079
142. Beuschlein, F. Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection / F. Beuschlein, J. Weigel, W. Saeger et al. // J Clin Endocrinol Metab, 2015. – Vol. 100. – P. 841–849.
143. Papathomas, T. An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma / T. Papathomas, E. Pucci, T. Giordano et al. // Am J Surg Pathol. – 2016. – Vol. 40. – P. 569-576.
144. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996; 119:161-170.
145. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112:963-970; discussion, 970-971.
146. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg. 1992; 16:663-667; discussion, 668.
147. Abiven-Lepage G, Coste J, Tissier F, et al. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. European Journal of Endocrinology. 2010;163: 793–800. doi:10.1530/EJE-10-0412
148. De Corbiere P, Ritzel K, Cazabat L, et al. Pregnancy in women previously treated for an adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism. 2015;100: 4604–4611. doi:10.1210/jc.2015-2341
149. Asare EA, Wang TS, Winchester DP, et al. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery. 2014; 156:1378–1386. doi:10.1016/j.surg.2014.08.018
150. Всероссийское общество редких (орфанных) заболеваний (http://akr.rare-diseases.ru/)
151. Pennanen, M. Helsinki score—a novel model for prediction of metastases in adrenocortical carcinomas / M. Pennanen, I. Heiskanen, T. Sane et al. // Human Pathology. – 2015. – Vol. 46, N 3. – P. 404-410.
152. Hough, A.J. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data / A.J. Hough, J.W. Hollifield, D.L. Page et al. // Am J Clin Pathol. – 1979. – Vol. 72. – P. 390-399.
153. Aubert, S. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors / S. Aubert, A. Wacrenier, X. Leroy et al. // Am. J. Surg. Pathol. – 2002. – Vol. 26, №12. – P. 1612-1619.
154. Duregon E. et al. The Reticulin Algorithm for Adrenocortical Tumor Diagnosis // Am. J. Surg. Pathol. 2013. Vol. 37, № 9. P. 1433–1440.
155. Cosentini D, Badalamenti G, Grisanti S et al. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019 Dec;181(6):681-689. doi: 10.1530/EJE-19-0570. PMID: 31639772.
156. Libe R, Dall’Asta C, Barbetta L et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002; 147:489–494. doi: 10.1530/eje.0.1470489
157. Gardet V et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens. 2001;19(6):1029-1035. 10.1097/00004872-200106000-00006
158. Pacak K et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134(4):315-329. doi: 10.7326/0003-4819-134-4-200102200-00016
159. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644.
160. Welch TJ, Sheedy PF II, Stephens DH et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193:341-344
161 Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007; 3:92-102
162. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003; 169:5-11
163. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163-169.
164. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40(6):757-768.
165. Van Slooten H, Schaberg A, Smeenk D, Moolenar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985 Feb 15;55(4):766-773.
166. Blanes A et al. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007;127(3):398-408.
167. Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol. 2005;89(3):186-92. doi: 10.1002/jso.20180
168. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6:386-394.
169. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000; 33:1197-1200
170. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf). 1989; 31:51-57
171. Министерство здравоохранения Российской Федерации. Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения. https://www.rosminzdrav.ru/
172. Lim MC, Tan YO, Chong PY, Cheah JS. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore. 1990.
173. Decker RA, Kuehner ME. Adrenocortical carcinoma. Am Surg. 1991; 57:502-513.
174. Terzolo, M. Adjuvant mitotane treatment for adrenocortical carcinoma / M. Terzolo Angeli A, Fassnacht M et al. // N. Engl. J. Med. – 2007. – Vol. 356, №23. – P. 2372-2380.
175. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest. 2001; 24:532-535.
176. Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92:1385-1392.
177. Heilmann P, Wagner P, Nawroth PP, Ziegler R [Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD). Therapeutic management by monitoring o,p_-DDD blood levels]. Med Klin. 2001; 96:371-377
178. Becker D, Schumacher OP. o,p’DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med. 1975; 82:677-679.
179. Boven E, Vermorken JB, van Slooten H, PinedoHM. Complete response of metastasized adrenal cortical carcinoma with o,p_-DDD. Case report and literature review. Cancer. 1984; 53:26-29.
180. Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant Mitotane for Adrenocortical Cancer—Working through Uncertainty. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(6):1879–1880. doi:10.1210/jc.2009-0120
181. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology; 2011; 75:585–591. doi:10.1111/j.1365-2265.2011.04214.x
182. Cordon-Cardo C, O'Brien JP, Boccia J et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38:1277-1287.
183. Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112:981-986.
184. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81:116-124.
185. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. An-ticancer Res. 1994; 14:1009-1016.
186. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer. 1993;29A:1036-1038.
187. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445-53.
188. Papotti, M. The Weiss score and beyond – histopathology for adrenocortical carcinoma / M. Papotti, R. Libè, E. Duregon et al. // Horm. Cancer. – 2011. – Vol. 2, №6. – P. 333-340.
189. Volante, M. Pathological and molecular features of adrenocortical carcinoma: an update / M. Volante, C. Buttigliero, E. Greco et al. // J. Clin. Pathol. – 2008. – Vol. 61.– №7. – P. 787–793.
190. Adrenal Cortical Carcinoma. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017.
191. Libe, R. Prognostic factors in stage III-IY adrenocortical cancinoma (ACC): an European Network for the study of adrenal tumor (ENSAT) study / R. Libe, I. Borget, L. Ronchi // Annals of Oncology. - 2015. - Vol. 26. - P. 2119-2125.
192. Бохян, В.Ю., Павловская А.И., Губина Г.И., Стилиди И. С. Клиническая оценка гистологических систем диагностики адренокортикальных опухолей // Архив патологии. - 2015. - №3. - Т. 77. - Стр. 17-22.
193. Fassnacht M, Kenn W & Allolio B. Adrenal tumors: How to establish malignancy? J Endocrinol Invest 2270 2004 27 387-399.
194. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al.: Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 45 (3): 265-73, 2005.
195. Zancanella P, Pianovski MA, Oliveira BH, et al.: Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J Pediatr Hematol Oncol 28 (8): 513-24, 2006.
196. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998; 83:2194–2200
197. Майстренко Н.А., Ромащенко П.Н., Бабич А.И. Современные подходы к диагностике и лечению злокачественных новообразований надпочечников // Мед. акад. журн. – 2011. – Т. 11, №2. – С. 117-126.
198. Бабич А.И., Ромащенко П.Н., Орлова Р.В., Бабич А.И. Адренокортикальный рак: диагностика и лечение // Вестн. Рос. Воен.-мед. акад. – 2014. – №2. – С. 214-215.
199. Майстренко Н.А., Орлова Р.В., Ромащенко П.Н., Бабич А.И. Комбинированное лечение местно-распространенного адренокортикального рака [Электронный ресурс] / // Медлайн.Ру. – 2014. – Т. 15. – С. 495-497. – Режим доступа: http://www.medline.ru/public/art/tom15/art59.html.
200. Fassnacht M. et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors // Eur J Endocrinol. EJE. 2018. Vol. 179, №4. P. G1-G46.
201. Araujo-Castro M et al. Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance // Biomedicines. 2021. Vol. 9 №3. P. 304.
202. Georgantzoglou N. et al. Tumor microenvironment in adrenocortical carcinoma: Barrier to immunotherapy success? // Cancers (Basel). 2021. Vol. 13, № 8. P. 1–19.
203. De Reyniès A. et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival // J. Clin. Oncol. 2009. Vol. 27, № 7. P. 1108–1115.
204. Giordano T.J. et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling // Clin. Cancer Res. 2009. Vol. 15, № 2. P. 668–676.
205. Assié G. et al. Integrated genomic characterization of adrenocortical carcinoma // Nat. Genet. Nature Publishing Group, 2014. Vol. 46, № 6. P. 607–612.
206. Chabre O. et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients // Endocr. Relat. Cancer. 2013. Vol. 20, № 4. P. 579–594.
207. Soon P.S.H. et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer // Clin. Cancer Res. 2009. Vol. 15, № 24. P. 7684–7692.
208. Barreau O. et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas // J. Clin. Endocrinol. Metab. 2013. Vol. 98, № 1. P. 174–184.
209. Mohan D.R. et al. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma // Clin Cancer Res. 2019. Vol. 25 №11. P. 3276-3288.
210. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. Endocrinol Invest. 2014;37(3):207-17. doi: 10.1007/s40618-013-0049/
211. Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical Carcinoma with Hypercortisolism. Endocrinol Metab Clin North Am. 2018 Jun;47(2):395-407. doi: 10.1016/j.ecl.2018.02.003. Epub 2018 Apr 9. PMID: 29754640.
212. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, Else T. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013 Aug 20;31(24):3012-8. doi: 10.1200/JCO.2012.48.0988. Epub 2013 Jul 22. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612. PMID: 23752102; PMCID: PMC3739861.
213. suboi I, Kardoust Parizi M, Matsukawa A, Mancon S, Miszczyk M, Schulz RJ, Fazekas T, Cadenar A, Laukhtina E, Kawada T, Katayama S, Iwata T, Bekku K, Wada K, Remzi M, Karakiewicz PI, Araki M, Shariat SF. The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis. Urol Oncol. 2024 Oct 7:S1078-1439(24)00654-9. doi: 10.1016/j.urolonc.2024.09.014. Epub ahead of print. PMID: 39379210.
214. Горбунова В.А., Бельцевич Д.Г., Бохян В.Ю. и соавт. Рак коры надпочечника. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):445–451.
215. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Nov;31(11):1476-1490. doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27. Erratum in: Ann Oncol. 2023 Jul;34(7):631. doi: 10.1016/j.annonc.2022.12.006. PMID: 32861807.
216. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2025. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2025.
217. Zhulikov YA, et al. Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study. Ann Oncol. 2024;35(Suppl): S537.
218. Laganà M, Grisanti S, Ambrosini R, Cosentini D, Abate A, Zamparini M, Ferrari VD, Gianoncelli A, Turla A, Canu L, Terzolo M, Tiberio GAM, Sigala S, Berruti A. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open. 2022 Apr;7(2):100422. doi: 10.1016/j.esmoop.2022.100422. Epub 2022 Mar 7. PMID: 35272132; PMCID: PMC9058897.
219. Oldenburger E, Brown S., Willmann J., et al ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022 Aug; 173:240-253. doi: 10.1016/j.radonc.2022.06.002.
220. Фогт С.Н., Калугина В.В., Ворохобина Н.В., Кузнецова А.В., Серебрякова И.П. Текущий статус лекарственной терапии аденокортикального рака. Медицинский вестник Юга России. 2022;13(2):154-161. https://doi.org/10.21886/2219-8075-2022-13-2-154-161.
221. Cifu D. X., Lew H. L. Braddom s Rehabilitation Care: A Clinical Handbook E-Book. – Elsevier Health Sciences, 2017.
222. Van den Berg J. P. et al. Guideline" Cancer rehabilitation" //Nederlands tijdschrift voor geneeskunde. – 2011. – Т. 155. – №. 51. – С. A4104.
223. Fu J. B., Morishita S. The future of rehabilitation in oncology. – 2017.
224. Poirier J, Godemel S, Mourot A, Grunenwald S, Olney HJ, Le XK, Lacroix A, Caron P, Bourdeau I. Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2336-2342. doi: 10.1210/clinem/dgad115. PMID: 36856782.
225. Magkou D, Do Cao C, Bouvattier C, Douillard C, de Marcellus C, Cazabat L, Gérard M, Raffin-Sanson ML, Young J. Foetal exposure to mitotane/Op'DDD: Post-natal study of four children. Clin Endocrinol (Oxf). 2018 Dec;89(6):805-812. doi: 10.1111/cen.13854. Epub 2018 Oct 16. PMID: 30222204.
226. Жуликов Я.А. Лекарственная терапия и роль повторных хирургических вмешательств в лечении местнораспространенного и метастатического адренокортикального рака: дис. ... канд. мед. наук: 3.1.6 – Онкология, лучевая терапия / ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России. – М., 2025.
227. Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M. Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review. Cancers (Basel). 2021 Oct 5;13(19):5001. doi: 10.3390/cancers13195001. PMID: 34638485; PMCID: PMC8508479.
228. Ma S, Wu L, Ye L, Habra MA, Balderrama-Brondani V, Wang W. Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma. Endocrine. 2025 Jan 25. doi: 10.1007/s12020-025-04163-5. Epub ahead of print. PMID: 39862362.
229. Ribeiro R, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer. 2004;40(8):1117–1126. doi: 10.1016/j.ejca.2004.01.031
230. Kuhlen M, Mier P, Kunstreich M, Lessel L, Slavetinsky C, Fuchs J, Seitz G, Holterhus PM, Wudy SA, Vokuhl C, Frühwald MC, Vorwerk P, Redlich A. Locally Advanced Adrenocortical Carcinoma in Children and Adolescents-Enigmatic and Challenging Cases. Cancers (Basel). 2023 Aug 28;15(17):4296.
231. Rodriguez-Galindo C., Krailo M.D., Pinto E.M., Pashankar F., Weldon C.B., Huang L., Caran E.M., Hicks J., McCarville M.B., Malkin D., et al. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children’s Oncology Group ARAR0332 Protocol. J. Clin. Oncol. 2021;39:2463–2473.
232. Sandru F, Petca RC, Carsote M, Petca A, Dumitrascu MC, Ghemigian A. Adrenocortical carcinoma: Pediatric aspects (Review). Exp Ther Med. 2022 Apr;23(4):287.
233. Pinto EM, Zambetti GP, Rodriguez-Galindo C. Pediatric adrenocortical tumours. Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101448. doi: 10.1016/j.beem.2020.101448. Epub 2020 Jul 3.
234. Berthold F., Simon T. Clinical presentation // Neuroblastoma. 2005. P. 63–86.
235. Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. Front Pediatr. 2017 Jul 13;5:155.
236. Berthold F. NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma Principal investigator [Electronic resource]. 2004. URL: http://nodgo.org/sites/default/files/protokol_neuroblastoma-1.pdf (accessed: 12.12.2019).
237. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006 Aug;1073:30-7. doi: 10.1196/annals.1353.003.
238. Ilanchezhian M, Varghese DG, Glod JW, Reilly KM, Widemann BC, Pommier Y, Kaplan RN, Del Rivero J. Pediatric adrenocortical carcinoma. Front Endocrinol (Lausanne). 2022 Oct 31;13:961650.
239. Xia J. et al. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis // J. Huazhong Univ. Sci. Technol. - Med. Sci. 2017. Vol. 37, № 5. P. 649–660.
240. Riedmeier M, Antonini SRR, Brandalise S, Costa TEJB, Daiggi CM, de Figueiredo BC, de Krijger RR, De Sá Rodrigues KE, Deal C, Del Rivero J, Engstler G, Fassnacht M, Fernandes Luiz Canali GC, Molina CAF, Gonc EN, Gültekin M, Haak HR, Guran T, Hendriks Allaird EJ, Idkowiak J, Kuhlen M, Malkin D, Meena JP, Pamporaki C, Pinto E, Puglisi S, Ribeiro RC, Thompson LDR, Yalcin B, Van Noesel M, Wiegering V. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects. Eur J Endocrinol. 2024 Mar 30;190(4):G15-G24.
241. Kuhlen M, Mier P, Kunstreich M, Lessel L, Schneider D, Brecht I, Schewe DM, Frühwald MC, Vorwerk P, Redlich A. Key factors for effective mitotane therapy in children with adrenocortical carcinoma. Endocr Relat Cancer. 2022 Aug 1;29(9):545-555.
242. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4.
243. Driver CP, Birch J, Gough DC, Bruce J. Adrenal cortical tumors in childhood. Pediatr Hematol Oncol (1998) 15:527–32.
244. Virgone C, Roganovic J, Vorwerk P, Redlich A, Schneider DT, Janic D, Bien E, López-Almaraz R, Godzinski J, Osterlundh G, Stachowicz-Stencel T, Brugières L, Brecht IB, Thomas-Teinturier C, Fresneau B, Surun A, Ferrari A, Bisogno G, Orbach D. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29025.
245. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 Feb;101(2):364-89. doi: 10.1210/jc.2015-1710. Epub 2016 Jan 13.
246. Head L, Kiseljak-Vassiliades K, Clark TJ, Somerset H, King J, Raeburn C, Albuja-Cruz M, Weyant M, Cleveland J, Wierman ME, Leong S. Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer. J Endocr Soc. 2019 Oct 11;3(12):2295-2304. doi: 10.1210/js.2019-00305. PMID: 31745526; PMCID: PMC6853671.
247. Gillespie EF, Lapen K, Wang DG, Wijetunga N, Pastrana GL, Kollmeier MA, Yamada J, Schmitt AM, Higginson DS, Vaynrub M, Santos Martin E, Xu AJ, Tsai C, Yerramilli D, Cahlon O, Yang T. Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016-2018. Clin Transl Radiat Oncol. 2020 Oct 8;25:75-80. doi: 10.1016/j.ctro.2020.10.001. PMID: 33102818; PMCID: PMC7575833.
248. Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, Hoskin PJ, Ball DL; Trans-Tasman Radiation Oncology Group, TROG 96.05. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr;75(1):54-63. doi: 10.1016/j.radonc.2004.09.017. Epub 2004 Oct 28. PMID: 15878101.
249. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer. 2010 Aug 16;17(3):797-807. doi: 10.1677/ERC-09-0341. PMID: 20592067.
250. Meeuse JJ, van der Linden YM, van Tienhoven G, Gans RO, Leer JW, Reyners AK; Dutch Bone Metastasis Study Group. Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life: results from the Dutch Bone Metastasis Study. Cancer. 2010 Jun 1;116(11):2716-25. doi: 10.1002/cncr.25062. PMID: 20225326.
251. https://www.sehop.org/wp-content/uploads/2015/07/ARAR0332.-T.-adrenocorticales.pdf